{
    "nctId": "NCT02154139",
    "briefTitle": "Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey \"Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)\"",
    "officialTitle": "Leuplin SR 11.25 mg for Injection Specified Drug-use Survey \"Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)\"",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 651,
    "primaryOutcomeMeasure": "Number of Participants Reporting One or More Adverse Drug Reactions",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Premenopausal breast cancer patients (patients with advanced or recurrent breast cancer and patients who received adjuvant therapy).\n\nExclusion Criteria:\n\n* Patients with a history of treatment with Leuplin SR 11.25 mg for Injection",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}